Hanmi launches South Korea's first homegrown GLP-1 obesity drug Epe, priced up to 40% below Mounjaro
Epe (epeglenatide) opens the domestic South Korean obesity market at roughly half Mounjaro's price, intensifying a global price war in GLP-1 therapies.
BigGo Finance · +6 outlets
FDA approves Merck's LIPFENDRA, the first oral PCSK9 inhibitor
An oral alternative to injectable PCSK9 cholesterol drugs broadens Merck's cardiovascular portfolio and pressures incumbents Amgen and Regeneron.
scanx.trade · +14 outlets
Inovio shares surge after FDA accelerated approval of VOCERYQ and a court win
The regulatory clearance hands Inovio its first approved product, though analysts flag a difficult commercial path ahead.
StocksToTrade · +7 outlets
FDA advisers narrowly vote to add six peptides to the drug compounding list
The advisory vote could loosen compounding restrictions on peptide drugs, a closely watched issue amid the GLP-1 supply debate.
Health Affairs · +13 outlets
Regeneron posts record Q3 2026 results and an $8B Sanofi alliance
Record quarterly revenue and an expanded Sanofi collaboration reinforce Regeneron's pipeline funding position.
Investing.com India · +3 outlets
Gene editing shares jump on ESGCT data and FDA draft guidance
Positive conference data plus a new FDA draft guidance lifted gene-editing equities, a sector sensitive to regulatory signals.
Genetic Engineering and Biotechnology Ne · +1 outlets
India cancer drug price cuts: 159 of 643 brands saw no reduction, mark-ups up to 700% return
Analyses of India's cancer drug price reset show headline cuts averaging over 50% translate to only about a 14% overall reduction, with large mark-ups resurfaci
Health and Me · +10 outlets
AstraZeneca lung cancer combo cut progression-or-death risk 45% vs chemo; Europe and Japan review it
The Phase 3 readout supports filings for the combination in Europe and Japan, a key oncology growth driver for AstraZeneca.
Stock Titan · +6 outlets
China holds 21 of Asia-Pacific's 30 obesity drug candidates, South Korea six
The pipeline tally underscores how quickly Chinese and Korean developers have moved into GLP-1 and next-generation obesity programs.
아시아경제 · +1 outlets
Merck's Keytruda: from near miss to crown jewel, and the road ahead
A look at Keytruda's rise into the world's top-selling cancer drug and the patent-cliff challenges facing Merck.
RTTNews · +1 outlets
Eli Lilly's blowout earnings prompt debate on whether the stock is still a buy
Strong quarterly results from the obesity drug leader reignited valuation questions after a large share price run.
The Motley Fool · +1 outlets
Ascletis oral GLP-1 shows strong Phase 2 diabetes data with solid safety profile
Positive mid-stage results for an oral GLP-1 add to competition against injectable obesity and diabetes therapies.
TipRanks · +3 outlets
Sun Pharma ordered to halt eye drug output at its Assam plant
A manufacturing stop at the Assam facility raises quality and supply concerns for one of India's largest drugmakers.
TradingView · +5 outlets
Aspen Neuroscience offers IPO shares with 15 Parkinson's patients dosed
The cell therapy developer's listing tests investor appetite for early-stage neuroscience biotech.
Stock Titan · +5 outlets
Daewon Pharmaceutical enters Korea's 400 billion won P-CAB market
The move diversifies competition in South Korea's acid-reflux drug segment, where P-CABs are displacing older proton pump inhibitors.
머니투데이 · +2 outlets
United Therapeutics wins FDA trial clearance
The clearance allows the company to advance a clinical program, a catalyst for its pulmonary and organ-focused pipeline.
Simply Wall St · +14 outlets
MIRA's oral obesity drug SKNY-1 shows a different weight-loss profile in early research
Early data suggest non-semaglutide mechanisms could offer differentiated weight-loss effects, though the work is preclinical to early-stage.
Barchart.com
GRAIL expands Galleri access in Ontario
Broader Canadian availability of the multi-cancer early detection blood test extends GRAIL's commercial footprint.
Simply Wall St · +1 outlets